DK3927370T3 - Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf - Google Patents
Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf Download PDFInfo
- Publication number
- DK3927370T3 DK3927370T3 DK20711461.2T DK20711461T DK3927370T3 DK 3927370 T3 DK3927370 T3 DK 3927370T3 DK 20711461 T DK20711461 T DK 20711461T DK 3927370 T3 DK3927370 T3 DK 3927370T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- cells
- methods
- cancer treatment
- generating autologous
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/505—CD4; CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962807644P | 2019-02-19 | 2019-02-19 | |
US201962826974P | 2019-03-29 | 2019-03-29 | |
US201962941614P | 2019-11-27 | 2019-11-27 | |
US201962941610P | 2019-11-27 | 2019-11-27 | |
PCT/US2020/018711 WO2020172202A1 (en) | 2019-02-19 | 2020-02-18 | Methods for producing autologous t cells useful to treat cancers and compositions thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3927370T3 true DK3927370T3 (da) | 2024-05-21 |
Family
ID=69811963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK20711461.2T DK3927370T3 (da) | 2019-02-19 | 2020-02-18 | Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220135944A1 (da) |
EP (2) | EP3927370B8 (da) |
KR (1) | KR20210152464A (da) |
CN (1) | CN113710270A (da) |
AU (1) | AU2020226498A1 (da) |
BR (1) | BR112021016340A2 (da) |
CA (1) | CA3130578A1 (da) |
DK (1) | DK3927370T3 (da) |
IL (1) | IL285631A (da) |
MX (1) | MX2021009967A (da) |
PT (1) | PT3927370T (da) |
WO (1) | WO2020172202A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020391231A1 (en) * | 2019-11-27 | 2022-07-14 | Turnstone Biologics Corp. | Method of producing tumor-reactive T cell composition using modulatory agents |
CN115175988B (zh) * | 2020-12-24 | 2024-06-14 | 苏州沙砾生物科技有限公司 | 肿瘤浸润淋巴细胞的制备方法及其用途 |
CN116426483B (zh) * | 2021-12-30 | 2024-02-23 | 南京紫珑生物科技有限公司 | Cd258蛋白在免疫治疗中的应用 |
WO2023218399A1 (en) | 2022-05-11 | 2023-11-16 | Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud | Method of preparing and expanding a population of immune cells for cancer therapy, potency assay for tumor recognition, biological vaccine preparation and epitope target for antibodies |
WO2024098041A1 (en) * | 2022-11-04 | 2024-05-10 | Turnstone Biologics Corp. | Compositions and methods for generating neo-antigen reactive tumor infiltrating lymphocytes |
WO2024130212A1 (en) | 2022-12-16 | 2024-06-20 | Turnstone Biologics Corp. | Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985565A (en) | 1996-10-09 | 1999-11-16 | Temple University-Of The Commonwealth System Of Higher Education | Chronic fatigue syndrome diagnosis |
JP5070045B2 (ja) | 2004-05-27 | 2012-11-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規人工抗原提示細胞およびそれらの用途 |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
EP4169951A1 (en) | 2008-12-09 | 2023-04-26 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
CN104961829B (zh) | 2009-11-24 | 2018-08-21 | 米迪缪尼有限公司 | 针对b7-h1的靶向结合剂 |
KR101952965B1 (ko) | 2010-05-25 | 2019-02-27 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Bambam:고처리율 서열분석 데이터의 병렬 비교 분석 |
US9646134B2 (en) | 2010-05-25 | 2017-05-09 | The Regents Of The University Of California | Bambam: parallel comparative analysis of high-throughput sequencing data |
WO2012129201A1 (en) | 2011-03-22 | 2012-09-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
SG11201402603WA (en) | 2011-11-28 | 2014-06-27 | Merck Patent Gmbh | Anti-pd-l1 antibodies and uses thereof |
CN107074932A (zh) | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞受体的方法 |
AU2014407540C1 (en) * | 2014-10-02 | 2021-07-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of isolating T cells having antigenic specificity for a cancer-specific mutation |
CN116726047A (zh) * | 2017-03-31 | 2023-09-12 | 美国卫生和人力服务部 | 分离新抗原-特异性t细胞受体序列的方法 |
-
2020
- 2020-02-18 EP EP20711461.2A patent/EP3927370B8/en active Active
- 2020-02-18 CA CA3130578A patent/CA3130578A1/en active Pending
- 2020-02-18 PT PT207114612T patent/PT3927370T/pt unknown
- 2020-02-18 EP EP24162638.1A patent/EP4394032A2/en active Pending
- 2020-02-18 US US17/431,692 patent/US20220135944A1/en active Pending
- 2020-02-18 BR BR112021016340-9A patent/BR112021016340A2/pt unknown
- 2020-02-18 KR KR1020217030013A patent/KR20210152464A/ko unknown
- 2020-02-18 WO PCT/US2020/018711 patent/WO2020172202A1/en unknown
- 2020-02-18 AU AU2020226498A patent/AU2020226498A1/en active Pending
- 2020-02-18 DK DK20711461.2T patent/DK3927370T3/da active
- 2020-02-18 MX MX2021009967A patent/MX2021009967A/es unknown
- 2020-02-18 CN CN202080029584.9A patent/CN113710270A/zh active Pending
-
2021
- 2021-08-15 IL IL285631A patent/IL285631A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021016340A2 (pt) | 2021-10-26 |
EP3927370A1 (en) | 2021-12-29 |
WO2020172202A1 (en) | 2020-08-27 |
KR20210152464A (ko) | 2021-12-15 |
CA3130578A1 (en) | 2020-08-27 |
CN113710270A (zh) | 2021-11-26 |
EP3927370B8 (en) | 2024-06-05 |
EP3927370B1 (en) | 2024-04-24 |
IL285631A (en) | 2021-09-30 |
AU2020226498A1 (en) | 2021-10-14 |
EP4394032A2 (en) | 2024-07-03 |
MX2021009967A (es) | 2021-11-12 |
US20220135944A1 (en) | 2022-05-05 |
PT3927370T (pt) | 2024-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3927370T3 (da) | Fremgangsmåder til frembringelse af autologe T-celler, der kan anvendes til cancerbehandling, og sammensætninger deraf | |
DK3678668T3 (da) | ENPP1-inhibitorer og deres anvendelse til behandling af kræft | |
PH12020551923A1 (en) | Methods and compositions for treating cancer | |
IL282735A (en) | Preparations and methods for t-cell engineering | |
EA201992781A1 (ru) | Ингибиторы g12c kras и способы их применения | |
DK3775091T3 (da) | Stabiliserede fluorolefinsammensætninger og fremgangsmåder til fremstilling, oplagring og anvendelse deraf | |
DK3331900T3 (da) | Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere | |
DK3291830T3 (da) | Hidtil ukendte peptider og kombination af peptider og stilladser deraf til anvendelse ved immunterapi mod kolorektalt karcinom og andre cancere | |
IL280659A (en) | Processes for creating transgenic cells and their compounds | |
IL274299A (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
HK1255063A1 (zh) | 基因修飾的抗第三方中央型記憶t細胞及其在免疫療法中的用途 | |
DK3842429T3 (da) | Heterocykliske inhibitorer af ERK1 og ERK2 og anvendelse deraf i behandling af cancer | |
DK3430030T3 (da) | Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer | |
DK3157629T3 (da) | Fremgangsmåder til cancerbehandling med antagonister mod pd-1 og pd-l1 i kombination med strålebehandling | |
DK3134130T3 (da) | Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier | |
DK3490575T3 (da) | Planteekstrakt med høj koncentration af safranal, fremstillingsfremgangsmåde og anvendelser | |
DK3200815T3 (da) | Fremgangsmåder og sammensætninger til behandling af cancer | |
DK3902803T3 (da) | Aza-heterobicykliske inhibitorer af mat2a og anvendelsesfremgangsmåder til behandling af kræft | |
DK3775165T3 (da) | Fremgangsmåder til frembringelse af tumorinfiltrerende lymfocytter og anvendelser heraf i immunterapi | |
DK3319985T3 (da) | Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod øsofaguscancer og andre cancere | |
DK3460052T3 (da) | Forbedrede allogene dendrittiske celler til anvendelse i behandling af cancer | |
MX2020003605A (es) | Manipulación del metabolismo de triptamina. | |
DK3102232T3 (da) | Fremgangsmåder og sammensætninger til behandling af abnorm cellevækst | |
DK3402575T3 (da) | Fremgangsmåder og sammensætninger til behandling af beskadiget hår | |
DK3496743T3 (da) | Sammensætninger og fremgangsmåder til behandling af cancer med arginindepletering og immunonkologiske midler |